Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjunctival sac fluid of patients with diabetes affected by proliferative retinopathy

Diabetic Medicine

Volumn 28, Issue 10, 2011, Pages 1277-1278

  Secchiero, P ^a   Perri, P ^a   Melloni, E ^a   Martini, A ^a   Lamberti, G ^a   Sebastiani, A ^a   Zauli, G ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PIGMENT EPITHELIUM DERIVED FACTOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLINDNESS; CELL MATURATION; CELL PROLIFERATION; CONJUNCTIVA; DIABETIC RETINOPATHY; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; INFLAMMATORY CELL; LETTER; MYOFIBROBLAST; NONHUMAN; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA NEOVASCULARIZATION;

APOPTOSIS REGULATORY PROTEINS; BODY FLUIDS; CONJUNCTIVA; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 80052990735     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03202.x     Document Type: Letter

References (8)

1. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005; 438: 960-966.
2. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1-29.
3. Elayappan B, Ravinarayannan H, Pasha SP, Lee KJ, Gurunathan S. PEDF inhibits VEGF- and EPO-induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation. Angiogenesis 2009; 12: 313-324.
4. Hubert KE, Davies MH, Stempel AJ, Griffith TS, Powers MR. TRAIL-deficient mice exhibit delayed regression of retinal neovascularization. Am J Pathol 2009; 175: 2697-2708.
5. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, Zauli G. TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 2005; 105: 3413-3419.
6. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E et al. Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 2006; 114: 1522-1530.
7. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010; 6: 94-101.
8. Secchiero P, Lamberti G, Corallini F, Melloni E, Sebastiani A, Zauli G. Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye. J Cell Physiol 2009; 218: 199-204.